[1] Jung JM, Kang DW, Yu KH, et al. Predictors of recurrent stroke in patients with symptomatic intracranial arterial stenosis [J]. Stroke, 2012. 43(10): 2785-2787.
[2] Wang Y, Meng R, Liu G, et al. Intracranial atherosclerotic disease [J]. Neurobiol Dis, 2019, 124: 118-132.
[3] Hafeez A, Liu L, Ding Y. Ongoing progress and new developments in the clinical approach to stroke and cerebrovascular disease: new paradigms: a novel outlook into stroke [J]. Neurol Res, 2016, 38(6): 477.
[4] 陈康宁. 症状性动脉粥样硬化性椎动脉起始部狭窄血管内治疗中国专家共识[J]. 中华医学杂志，2015，95(9): 648-653.
[5] 缪中荣，凌锋，李慎茂，等. 支架辅助血管成形术在症状性颅内动脉狭窄治疗中的应用[J]. 中华医学杂志，2002， 82(10):657-660.
[6] 凌一童，孙玉杰，李广文，等. 雷帕霉素洗脱支架与金属裸支架治疗症状性颅内动脉粥样硬化性狭窄的效果比较 [J]. 中国卒中杂志，2022，17(5):529-534.
[7] Zhang Y, Chen F, Muramatsu T, et al. Nine-month angio- graphic and two-year clinical follow-up of polymer-free sirolimus-eluting stent versus durable-polymer sirolimus- eluting stent for coronary artery disease: the Nano randomized trial [J]. Chin Med J (Engl), 2014, 127(11): 2153- 2158.
[8] Qureshi AI, Kirmani JF, Hussein HM, et al. Early and inter- mediate-term outcomes with drug-eluting stents in high- risk patients with symptomatic intracranial stenosis [J]. Neurosurgery, 2006, 59(5): 1044-1051.
[9] Kim J, Ban SP, Kim YD, et al. Long-term outcomes of drug- eluting stent implantation in patients with symptomatic extra- and intracranial atherosclerotic stenoses [J]. J Cerebrovasc Endovasc Neurosurg, 2020, 22(4): 216-224.
[10] Hassan AE, Mohammaden MH, Rabah RR, et al. Initial experience with the next-generation resolute onyx zotaroli- mus-eluting stent in symptomatic intracranial atherosclerotic disease [J]. Front Neurol, 2020, 11: 570100.
[11] 钟旋旋，于挺敏. 214 例急性缺血性卒中病人抗血小板药物反应性的观察及影响因素的探究[J]. 中国实验诊断学，2020，24(1):17-20.
